Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioMarin Pharmaceutical
Biotech
BioMarin axes 4 candidates, centers R&D around 3 assets
BioMarin is prioritizing three of its “most productive” assets, leaving four candidates on the wayside in a move expected to save up to $60 million.
Gabrielle Masson
Apr 25, 2024 10:10am
BioMarin hires ex-Roche leader Hubbard as CCO—Chutes & Ladders
Mar 8, 2024 9:30am
BioMarin CEO replaces commercial chief—Chutes & Ladders
Jan 19, 2024 8:30am
Longtime BioMarin CEO hands off baton—Chutes & Ladders
Nov 3, 2023 9:30am
BioMarin looks to up pace of new drug filings
Sep 12, 2023 3:58pm
FDA OKs companion Dx with BioMarin hemophilia gene therapy
Jun 30, 2023 10:35am